Trevena Inc (TRVN)

NASDAQ
0.1962
+0.0233(+13.48%)
Pre Market
0.2051
+0.0089(+4.54%)
- Real-time Data
  • Volume:
    1,597,564
  • Day's Range:
    0.1712 - 0.2048
  • 52 wk Range:
    0.1500 - 1.2000

TRVN Overview

Prev. Close
0.1729
Day's Range
0.1712-0.2048
Revenue
378K
Open
0.1712
52 wk Range
0.15-1.2
EPS
-0.358
Volume
1,597,564
Market Cap
34.08M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
948,772
P/E Ratio
-0.583
Beta
1.76
1-Year Change
-83.23%
Shares Outstanding
173,681,085
Next Earnings Date
Nov 09, 2022
What is your sentiment on Trevena Inc?
or
Market is currently closed. Voting is open during market hours.

Trevena Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Trevena Tops Q2 EPS by 1c
    • ByInvesting.com-

    Trevena (NASDAQ:TRVN) reported Q2 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).

  • TUP and ALGN among premarket losers
    • BySeeking Alpha-

    AC Immune SA (NASDAQ:ACIU) -50% after discontinuing Phase III CREAD 1 and 2 studies of Crenezumab.Tupperware Brands (NYSE:TUP) -18% on Q4 earnings.Trevena (NASDAQ:TRVN) -16% after...

Trevena Inc Analysis

Trevena Inc Company Profile

Trevena Inc Company Profile

Employees
0

Trevena Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. It is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. It is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. It is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The Company is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The Company is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.

Read More

Analyst Price Target

Average3.1667 (+1514.02% Upside)
High4
Low2
Price0.1962
No. of Analysts3
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyNeutralStrong Sell
Technical IndicatorsStrong SellStrong SellStrong BuyBuyStrong Sell
SummaryStrong SellNeutralStrong BuyNeutralStrong Sell
  • gogogooo!
    0
    • The company becan trial of covid 19 medicine.. if all goes well then we might get good results
      0
      • Very interesting to see what they do with all that cash. They've been definitely using it according to increase in liabilities. Very liquid, no debt.
        0
        • anyone long?
          0
          • is there any news ?
            0
            • i am not used to see this stock positive for a while.
              0
            • agreed
              0
            • https://www.google.com/amp/s/seekingalpha.com/amp/article/4400684-trevenas-catalyst-filled-q1
              0
          • Lets hit the 4 and then 7, that would make my day :)
            0
            • Boo
              0
              • Whats ur thoughts on this one guys? Ever gonna shine?
                0
                • dont think so in short term
                  0
              • https://www.trevena.com/investors/press-releases/detail/244/trevena-inc-announces-dea-scheduling-of-olinvyk
                0
                • $5 in November.2021 is where the real growth will start. BUY
                  1